Saffron76: Not sure how you worded the question...but possibility in regards to their eventual up list.
They need/are strengthening their management [requirement] they also need to be in a stronger cash position which they also have/are working on. Cash from warrants that will be exercised at $1.00 should give settle that requirement, then they need a share price most likely $3 or better.
Would like to see them get to that S/P without another R/S, it looks like right now there are many watching and looking for catalysts like initiation of TNBC Phase 11/Ovarian trial, Fast track and/or Orphan status approval may move us close to $1.
By 2nd quarter of 2016 we should have all catalysts in place knowledge of outcome on the Orphan and Fast track, initiation of at least the TNBC/Ovarian and possibly the Her2Nue breast cancer trial.
Any news such as increased Patent protection, grants, partnerships etc I believe will move us into the $2 to $4 dollar bracket, hence making the up list possible without R/S [mid 2016]
It is exciting right now because if Recurrence to disease passes previous marketed products [eg Herceptin] then that changes the game considerably to the upside, along with any BP collaboration news.
An influx of all those possible scenarios, I think puts us well above $4...but having said that we are on the OTC and will affect us negatively respective to news.
I would like to see them let the science and great news get them to the up list, so have patience saffron it certainly looks like we will get there sooner than later.
There are nothing but positives on the horizon right now and the trading looks like the stock is primed and ready to break out, remember that we are still very, very undervalued at these prices should be $2/3 at this point in regards to others in the space with comparative technology.
I am being very conservative [always am in my investing process] believe that their science is going to be very sought after when the Phase 11 trials are up and running.
In my opinion they have/are already doing DD on possible offers from BP, need to get Polystart into Phase 1 and finish license/IND for the Her2.
Management is doing a great job getting the company into position to up list, better to have a strong company in all aspects then to rush and run into problems 2016/2017.
Hope that helps.
GLTA
BLU
